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ABSTRACT 
BACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment 
with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major 
adverse cardiac events (MACE) in the short term.  
METHODS: Here we review studies using more potent antithrombotic agent 
combinations to reduce this risk, namely triple therapy (TT) with the addition of 
an oral anticoagulant, PAR-1 antagonist, or cilostazol to DAPT (mainly aspirin 
and clopidogrel), and discuss the limitations of trials to date. 
RESULTS: Generally speaking, TT leads to an increase in bleeding. Vorapaxar 
showed a signal for reducing ischaemic events, but increased intracranial 
haemorrhage 3-fold in the subacute phase of ACS, although remains an option for 
secondary prevention beyond the immediate subacute phase, particularly if 
prasugrel or ticagrelor are not available. Non-vitamin K oral anticoagulants 
(NOACs) all increased bleeding, with only modest reduction in MACE noted with 
low dose rivaroxaban. Rivaroxaban can be considered combined with aspirin and 
clopidogrel in ACS patients at high ischaemic and low bleeding risk, without prior 
stroke/TIA. The combination of P2Y12 inhibitor and NOAC, without aspirin, looks 
promising. DAPT may be replaced, not by TT, but by dual therapy comprising a 
NOAC with a P2Y12 inhibitor.  
CONCLUSION: More potent antithrombotic regimens increase bleeding and 
should only be considered on an individual basis, after careful risk stratification. 
Accurate risk stratification of ACS patients, for both ischaemic and bleeding risk, 
is essential to allow individualised treatment. 
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INTRODUCTION 
 
Patients with ACS are treated with dual antiplatelet therapy (DAPT), namely the 
combination of aspirin with a P2Y12 inhibitor, to reduce the risk of future thrombotic 
events. ACS most commonly results from rupture or fissure of a thin-cap fibrous 
atheroma within the coronary arterial tree. This results in exposure of plaque contents 
to flowing blood, which leads to platelet activation, and release of tissue factor 
leading to activation of coagulation(1-3). Activation of the coagulation pathway 
results in conversion of clotting factor X to Xa, which is a vital mediator in the 
formation of thrombin, the key modulator of the formation and stability of the 
platelet-rich plug (4) (figures 1 and 2).   
The acute management of ACS therefore involves the use of antiplatelet agents and 
anticoagulants. This is an integral step to counteract the prothrombotic state that 
results from active platelet aggregation(5). Current medical treatment involves the use 
of aspirin and a P2Y12 inhibitor(6), as well as anticoagulants, in particular low 
molecular weight heparin in the acute phase. As a general principle, the inhibition of 
multiple thrombotic pathways maximizes the antithrombotic effect in reducing future 
ischaemic events in ACS patients(5, 6).  
 
Rationale for current pharmacotherapy for ACS 
Over the last two decades, increasingly potent antiplatelet agents have been 
introduced to reduce the risk of arterial thrombosis, especially in high-risk groups 
such as patients with ACS. Clopidogrel was added to aspirin after the results of the 
Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) 
trial(7), which demonstrated that the addition of clopidogrel to aspirin in NSTE-ACS 
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significantly reduced the combined endpoint of CV death, MI and stroke (7, 8). More 
potent antiplatelet agents were introduced at least in part because of concerns that 
some 30% of patients taking clopidogrel exhibit high on-treatment platelet reactivity 
(HTPR)(9, 10). Subsequently, prasugrel was shown to be superior to clopidogrel in an 
ACS population undergoing PCI, with significant reduction in the risk of  CV death, 
MI, stroke (p<0.001) and stent thrombosis (p<0.001), at a cost of significant increase 
in major bleeding  (p=0.03)(11), but not superior in ACS patients who were not 
undergoing revascularization (12). Ticagrelor significantly reduced the occurrence of 
CV death, MI and stroke, compared to clopidogrel in ACS patients, with less stent 
thrombosis, but an overall increase in major bleeding(13). 
Despite potent antiplatelet agents, some ~10% of ACS patients experience a recurrent 
major adverse cardiovascular events (MACE) over the subsequent 30 days(14-18). 
This ongoing thrombotic risk led to the proposal for additional inhibition of 
thrombotic pathways. In the acute phase, GPIIb/IIIa inhibitors (GPI) or bivalirudin, a 
direct thrombin inhibitor, have been used with success to reduce ischaemic 
events(19). However, beyond the acute admission, acute thrombotic events continue 
to occur, particularly in the first 30 days, and so additional agents have been added to 
DAPT to try and minimise this risk. 
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TRIPLE THERAPY COMBINATIONS IN ACS 
 
Warfarin 
 
The addition of a vitamin K antagonist (VKA) to aspirin for the treatment of ACS 
resulted in a significant reduction in all ischaemic events (myocardial infarction, 
repeat revascularization, ischaemic stroke) with a three to four fold increase in major 
bleeding when compared to aspirin monotherapy(20, 21), but for this benefit to be 
realised required a very tight therapeutic window for warfarin (international 
normalized ratio 2-3) and the trials were conducted before DAPT became established 
as standard of care. Addition of warfarin to DAPT after ACS has only been assessed 
in small registries with results showing frequent bleeding events(22). In a nationwide 
Danish registry Sorensen and colleagues assessed 40,812 patients retrospectively after 
ACS who were treated with multiple different regimens including monotherapy with 
aspirin, clopidogrel, or warfarin; combination therapy with aspirin and clopidogrel, 
aspirin and warfarin and clopidogrel and warfarin; or triple therapy with all three 
agents. There was a three-fold increase in bleeding with the triple therapy compared 
to DAPT.  
The WOEST (What is the Optimal antiplatElet and anticoagulant therapy in patients 
with oral anticoagulation and coronary StenTing) study compared the combination of 
warfarin and clopidogrel against triple therapy comprising of warfarin, aspirin and 
clopidogrel in patients undergoing PCI with an indication for anticoagulation(23). In 
this open label, randomised controlled trial, the main indication for anticoagulation 
was atrial fibrillation and a third of the patients had ACS. Triple therapy was 
associated with a significant increase in bleeding compared to warfarin and 
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clopidogrel (44.4 vs 19.4% HR 0.36; p<0.0001) and also increased the rate of 
bleeding and the need for blood transfusion. In addition, triple therapy increased the 
risk of the composite of all-cause death, myocardial infarction, stroke, target vessel 
revascularization and stent thrombosis, driven mainly by increase in all-cause 
mortality (6.3 vs 2.5% p=0.0027). The ESC/EACTS Guidelines on myocardial 
revascularization therefore recommend reserving triple therapy with warfarin and 
DAPT to a short period after PCI in those with an indication for oral 
anticoagulation(24). 
 
Cilostazol 
 
Cilostazol is a selective phosphodiesterase III inhibitor that is shown to decrease 
platelet aggregation induced by collagen, 5'-adenosine diphosphate (ADP), 
epinephrine, and arachidonic acid. Unlike other antiplatelet agents, cilostazol not only 
inhibits platelet function but also improves endothelial cell function(25-27). Its 
additional benefit to current standard of care has been questioned with controversial 
results over the past decade(28, 29). A recent meta-analysis of 19 studies, comprising 
both randomised controlled trials and registries, compared aspirin and clopidogrel 
against triple therapy with cilostazol in 7464 patients with ACS undergoing PCI (30). 
Triple therapy was associated with a significant reduction in target vessel 
revascularization (RR 0.65, 95%; p<0.00001) but no difference in MACE or bleeding 
complications. In an updated meta-analysis of high risk ACS patients undergoing 
percutaneous revascularisation, triple therapy significantly reduced MACE, driven 
mainly by a reduction in all-cause mortality (OR 0.62, p<0.001) without an increase 
in bleeding compared to DAPT(31). Most of the studies included in both meta-
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analyses were conducted in East Asia, where there the frequency of the 
CYP2C19 loss-of-function allele carriers is >60% and the rate of HTPR on 
clopidogrel exceeds 50%, thus biasing the results against DAPT with clopidogrel. 
Cilostazol has not been combined with or compared against DAPT with prasugrel or 
ticagrelor. Cilostazol is not currently recommended by the European Society of 
Cardiology (ESC) or American College of Cardiology (ACC) nor is licensed for the 
treatment of ACS(24, 32, 33). 
 
Thrombin receptor antagonists 
 
Thrombin, being the most potent platelet activator and integral for fibrin formation, is 
the key mediator of arterial thrombotic events. The cellular effects of thrombin are 
mainly mediated via the protease-activated receptors (PAR), primarily PAR-1 and 
PAR-4, on the platelet surface (figure 1)(34). The rationale of inhibiting these 
pathways resulted in the development of two novel PAR-1 inhibitors, vorapaxar and 
atopaxar, as a way of preventing arterial thrombosis. Vorapaxar was assessed in two 
large phase III randomised controlled trials TRACER(35) and TRA-2P(36). 
In TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in ACS) 
12,944 patients presenting with NSTEMI were randomised to receive vorapaxar or 
placebo in addition to aspirin and clopidogrel (Table 1). Treatment of the index event 
included PCI (57.7%), CABG (10.1%) and medical therapy (32.2%). The addition of 
vorapaxar failed to reduce the composite of CV death, MI, stroke, recurrent ischemia 
requiring rehospitalisation and urgent revascularization. Bleeding rates were 
significantly higher in the vorapaxar group compared to placebo (7.2 vs 5.2%; 
p<0.001) with a threefold increase in intracranial haemorrhage (1.1 vs 0.2%; 
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p<0.001). As a result of this, the trial was terminated prematurely, although it is 
noteworthy that the secondary ischaemic endpoint of CV death, MI and stroke was 
significant lower in the vorapaxar group compared to placebo (14.7% vs 16.7%, HR 
0.89, 95% CI 0.81-0.98; p=0.002)(35). In a subsequent post hoc analysis, using 
multivariate risk stratification, vorapaxar showed a net clinical benefit of +2.8% in 
high ischaemic risk patients with low risk of bleeding(37). 
In the TRA-2P (Thrombin Receptor Antagonist in Secondary Prevention of 
atherothrombotic ischemic events) study, 26449 patients with prior MI, stroke or 
peripheral vascular disease (Table 1) were randomised to receive vorapaxar or 
placebo in addition to standard of care, which consisted of aspirin and clopidogrel for 
the MI population (62%). Vorapaxar reduced the composite of CV death, MI or stroke 
(9.3 vs 10.5%; p<0.001), driven by lower rate of MI (5.2 vs 6.1%; p<0.001), but 
increased bleeding (4.2 vs 2.5% HR 1.66 95% CI 1.43-1.93; p=0.001) as well as 
intracranial haemorrhage (1% vs 0.5%; p<0.001) leading to premature termination of 
the study for the stroke patients(36). In a subgroup analysis of the MI patients, 
vorapaxar significantly reduced the primary efficacy endpoint (p<0.001), particularly 
in high risk patients, with significant increase in bleeding (p<0.001)(38, 39).  
Following these positive results vorapaxar was approved for secondary prevention in 
high risk, stable patients with a history of MI and no previous stroke, in addition to 
aspirin or DAPT(40). It has not been approved as treatment of ACS. 
Atopaxar, another PAR-1 inhibitor, was evaluated in the phase II Lesson from 
Antagonizing the Cellular Effect of Thrombin-Acute Coronary Syndrome 
(LANCELOT-ACS) and Japanese-LANCELOT trials, exploring the safety and 
tolerability of different doses of atopaxar compared to placebo in addition to DAPT in 
ACS(41, 42). LANCELOT-ACS randomised 603 NSTEMI patients to receive 50mg, 
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100mg or 200mg of atopaxar versus placebo in addition to aspirin and clopidogrel or 
ticlopidine. Bleeding and the composite of CV death, MI, stroke or recurrent 
ischaemia, were similar in the atopaxar and placebo groups(41). Similar results were 
observed in the smaller Japanese-LANCELOT study, but with a dose-dependent 
transient increase in liver enzymes(41, 42) and dose-dependent QTc prolongation. As 
a result of these concerns, further trials with atopaxar were suspended. 
  
Non-vitamin K oral anticoagulants 
 
The introduction of newer non-vitamin K oral anticoagulants (NOACs) without the 
need for laboratory monitoring, few drug interactions and fixed daily dose regimens 
rekindled the idea of anticoagulation in high risk patients with ACS(43). 
The first randomised phase II control trial that evaluated a NOAC in patients with 
ACS was the ESTEEM trial(44). In this study, 1833 patients with recent ACS 
(>60%STEMI) were randomised to aspirin 160 mg or the combination of aspirin and 
ximelagatran, the first oral direct thrombin inhibitor, for 6 months. Importantly, this 
trial was done without concomitant use of an ADP receptor antagonist. Addition of 
ximelagatran was significantly superior to aspirin monotherapy for the combined 
primary endpoint of all-cause death, non-fatal MI and recurrent revascularization (HR 
0.76; p=0.036) and the secondary outcome of all-cause death, non-fatal MI and 
ischaemic stroke with an absolute risk reduction of 3.7% (p=0.0105). However, 
bleeding rates were numerically non-significantly higher on combination treatment, 
and furthermore, ximelagatran had a toxic liver profile and was never approved for 
clinical use.  
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Four oral factor Xa inhibitors, apixaban, rivaroxaban, darexaban, letaxaban, and the 
oral direct thrombin inhibitor, dabigatran, have been evaluated in phase II and phase 
III trials in patients with ACS. NOACs were used either in addition to aspirin 
monotherapy or in combination with DAPT after ACS(45-53). 
 
ATLAS ACS-TIMI 46(45) was a double blind, dose exploratory, phase II randomised 
controlled trial, to assess the efficacy and safety of different doses of rivaroxaban, in 
addition to DAPT or aspirin monotherapy in 3941 patients with recent ACS. Patients 
were initially randomised to receive 5mg, 10mg, 15mg or 20mg of rivaroxaban once 
or twice-daily doses or placebo. Patients were then randomised further to either 
receive aspirin monotherapy or the combination of aspirin and clopidogrel. 
Rivaroxaban, at all doses, failed to reduce the primary efficacy endpoint of the 
composite of all cause death, MI, stroke and severe recurrent ischemia requiring 
revascularization (p=0.10). Interestingly, rivaroxaban significant reduced the 
secondary end point of all cause death, stroke and MI, compared to placebo although 
the study was not powered to assess this. Clinically significant bleeding was increased 
in a dose-dependent manner in all triple therapy groups compared to DAPT 
(p<0.0001). 
Based on the above results, ATLAS ACS-TIMI 51, a phase III double blind, 
randomised controlled study was conducted to assess the safety and efficacy of the 
two lower doses of rivaroxaban (2.5mg bid and 5mg bid), against placebo, in addition 
to DAPT in 15,526 patients with ACS(46). The combined rivaroxaban dose 
significantly reduced the primary efficacy endpoint of cardiovascular death, MI and 
stroke compared to placebo (HR 0.84; p =0.002) at 1 year. In the analysis of the two 
doses of rivaroxaban, each dose reduced significantly the primary efficacy endpoint 
	 12	
(Table 1), however the 5mg dose did not reduce the risk of CV death (HR 0.94; 
p=0.63) compared to the 2.5mg dose (p=0.009). Rivaroxaban combined doses 
reduced significantly the secondary end point, consisting of all cause death, MI, 
stroke compared to placebo (HR 0.84; p=0.006). As expected, rivaroxaban combined 
doses significantly increased the rate of the primary safety endpoint, consisting of 
major bleeding (TIMI major bleeding not related to CABG) compared to placebo (HR 
3.96; p<0.001)(46). This was numerically lower for the 2.5mg dose however 
remained significant for both doses of rivaroxaban (Table 1). All bleeding events 
were significantly higher in the combined rivaroxaban doses compared to placebo 
with the exception of fatal bleeding. In a subgroup analysis of the STEMI-ACS 
population, rivaroxaban was found to reduce the primary efficacy end point compared 
to placebo (HR 0.81; p=0.019), a benefit that emerged as early as thirty days after the 
index event (p=0.042)(53). Interestingly, the low dose of rivaroxaban was the only 
one to significant reduce CV death when compared to placebo (p=0.006), whereas 
both doses significantly increased the rates of major bleeding (2.2% vs 0.6%, 
p<0.001) and intracranial haemorrhage (0.6% vs 0.1%, p=0.015) but not fatal 
bleeding (0.2% vs 0.1%, p=0.51)(53). In an additional subgroup analysis, combined 
doses of rivaroxaban significantly reduced all stent thrombosis compared to placebo 
(1.9% vs 1.5%; p=0.017) and the reduction was greater with the 2.5mg dose(54). 
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Based on these results, the 2015 ESC Guidelines for the management of acute 
coronary syndromes in patients presenting without persistent ST-segment elevation: 
Task Force for the Management of Acute Coronary Syndromes in Patients Presenting 
without Persistent ST-Segment Elevation of the European Society of Cardiology 
(ESC) state that rivaroxaban 2.5 mg twice daily, while not recommended in patients 
treated with ticagrelor or prasugrel, might be considered in combination with aspirin 
and clopidogrel if ticagrelor and prasugrel are not available for NSTEMI patients who 
have high ischaemic and low bleeding risks, with a class IIb recommendation with 
level of evidence B(32). It is contraindicated in patients with a prior history of 
ischaemic stroke/TIA and its use is cautioned in patients >75 years of age or <60 kg 
bodyweight.  
 
 
The Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) 
study was a phase II double blind, dose exploratory trial, to evaluate the safety and 
efficacy of apixaban, in addition to single or dual antiplatelet therapy versus placebo 
in 1715 patients with ACS(47). Patients with a recent ACS were randomised to 
receive 2.5mg, 10mg, 10mg, 20mg twice or once daily respectively or placebo. All 
patients received aspirin and the use of clopidogrel was left up to the treating 
physician resulting in overall 76% DAPT use, with predominantly clopidogrel. 
Apixaban, in a dose-dependent manner, significantly increased the rate of major or 
clinically relevant non-major bleeding compared to placebo (apixaban 2.5mg b.i.d HR 
1.78, 95% CI 0.91-3.48; p=0.09, apixaban 10mg o.d HR 2.45, 95% CI 1.31-4.61; 
p=0.005)(47). With the two lower doses of apixaban, a trend was seen towards 
reduction in the combination of CV death, MI, severe recurrent ischemia or ischaemic 
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stroke compared to placebo (apixaban 2.5mg b.i.d HR 0.73; p=0.21, apixaban 10mg 
o.d. HR 0.61; p=0.07)(47). 
Following these results, APPRAISE-2 study, a double blind, phase III randomised 
controlled trial, comparing the combination of DAPT with apixaban 5mg b.i.d versus 
placebo was undertaken in 10,800 patients with a recent ACS(48). The primary 
efficacy endpoint of the composite of CV death, MI and ischaemic stroke was no 
different between patients on apixaban and those on placebo (HR 0.95; p=0.51) and 
furthermore, the study had to be terminated early at a mean follow up of eight months, 
due to a significant increase in major bleeding in the apixaban arm (HR 2.59,; 
p=0.001)(48). Further analysis showed a significant increase in all bleeding outcomes 
with apixaban versus placebo, including fatal bleeding. 
The APPRAISE-J trial was a double blind, phase II randomised controlled trial, to 
assess the safety and efficacy of apixaban 2.5mg b.i.d, or 5mg b.i.d or placebo in 
addition to DAPT in Japanese patients with ACS(51).This study was able to only 
recruit 151 patients before it was terminated early due to the results of the 
APPRAISE-2 trial(48, 51). 
 
Darexaban, a factor Xa inhibitor, was examined in the RUBY-1 trial(50). RUBY-1 
was a double-blind dose-escalating phase II randomised controlled trial, to assess 
efficacy and safety of different doses and regimens of darexaban versus placebo in 
addition to DAPT, in 1279 patients with recent ACS(50). Patients were randomised to 
receive 10mg o.d, 30mg o.d, 60mg o.d, 5mg b.id, 15mg b.i.d, 30mg b.i.d of darexaban 
or placebo, in addition to DAPT with aspirin and clopidogrel. Darexaban significantly 
increased the rates of major bleeding compared to placebo in a dose-dependent 
fashion (HR 2.275; p=0.022)(50). The study was not powered to assess efficacy 
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outcomes, however there was no significant difference between darexaban and 
placebo(50). 
 
AXIOM was a double blind, phase II dose exploratory trial, to assess the safety and 
efficacy of letaxaban compared to placebo in combination with DAPT, in 2753 
patients with ACS(52). There was no difference in major bleeding between letaxaban 
and placebo, but when evaluated for a composite of TIMI major and minor bleeding 
outcome, letaxaban showed a significant dose-dependent increase in bleeding 
compared to placebo (2.1 vs 0.9%, p=0.025). Although not powered to assess efficacy 
endpoints, there were no observed differences between letaxaban and placebo for the 
composite of CV death, nonfatal MI, stroke or MI hospitalization(52). 
 
Among the first clinically available NOACs was dabigatran, a direct thrombin 
inhibitor, in contrast to other NOACs, that target factor Xa. The efficacy and safety of 
dabigatran in ACS was evaluated in the RE-DEEM study(49). This double blind, 
phase II, randomised controlled trial, examined 1861 patients with recent ACS to 
assess the combination of different doses of dabigatran against placebo, in addition to 
DAPT. Patients were randomised to receive 50mg b.i.d, 75mg b.i.d, 110 mg b.i.d and 
150mg b.i.d of dabigatran or placebo for six months. Dabigatran significantly 
increased major bleeding compared to placebo in a dose-dependent manner 
(p<0.001). Additionally, patients older than 75 years and female had a higher 
incidence of bleeding with the 110mg and 150mg doses(49). The most prevalent 
source of bleeding was gastrointestinal (3%) with no intracranial bleeding observed. 
The two higher doses of dabigatran, 110mg b.id and 150mg b.i.d, were associated 
with a numerical reduction in the composite end point of CV death, non-fatal MI and 
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non-haemorrhagic stroke when compared to placebo, however this was of not 
statistically significant(49). 
A meta-analysis of 7 published randomised, placebo-controlled phase II and III 
studies of NOACs (apixaban, dabigatran, darexaban, rivaroxaban, and ximelagatran) 
in addition to single (aspirin) or dual (aspirin and clopidogrel) antiplatelet therapy in 
ACS concluded that the addition of NOAC to DAPT reduced the rate of MACE (all-
cause mortality, myocardial infarction and stroke) by 13% (HR 0.85; p=0.85) at the 
expense of significantly increased major bleeding (HR 2.34; p<0.001)(55).  
 
Discussion 
 
In an effort to reduce recurrent ischaemic events in patients with ACS, investigators 
have explored the use of triple therapy, using an oral anticoagulant, PAR1 antagonist 
or cilostazol in addition to DAPT comprising predominantly of aspirin and 
clopidogrel. As a broad generalisation, in patients with a recent ACS, triple therapy 
leads to a significant increase in bleeding, and this is unacceptably high with 
vorapaxar and with warfarin. There appears to be a definite signal for all triple 
therapy combinations to reduce MACE compared to DAPT. The risk:benefit ratio in 
ACS patients seems to be acceptable to justify the use of rivaroxaban and possibly 
dabigatran in triple therapy combinations in high risk patients(45-52).  
However, some important points about need consideration when comparing the 
results of studies to date and drawing conclusions, which are outlined here. 
 
Assessing bleeding risk 
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The increased risk of bleeding is a universal theme in the studies where NOAC has 
been added to DAPT. A recent network meta-analysis showed that compared to 
aspirin monotherapy, major bleeding was increased up to 2-fold with DAPT, and 2–6-
fold with triple therapy(56). We feel some of this could have been mitigated against.  
The source of bleeding was most commonly gastrointestinal in the APPRAISE and 
RE-DEEM studies with an incidence up to 5%(47-49, 57) yet the use of 
gastroprotection with a proton pump inhibitor was not common, and used in less than 
a quarter of patients in APPRAISE-2 (48). Identifying patients at high risk of bleeding 
is challenging, especially when there is no universally accepted scoring system in the 
setting of ACS. Patients in the ATLAS ACS-TIMI 46 and ATLAS ACS-TIMI 51 
were younger and main exclusion criteria consisted of previous gastrointestinal bleed 
in the year preceding randomisation, any intracranial bleed and absolute haemoglobin 
< 10 g/dl(45, 46). In contrast to this, the population in the APPRAISE-2 study did not 
have these limitations in the exclusion criteria and patients were included with a 
haemoglobin  >9 g/dl(48).   
Given the increased risk of intracranial haemorrhage in patients with prior stroke 
treated with vorapaxar, perhaps this is another group where caution should be 
exercised in future trials of triple therapy.  
There are several bleeding risk score calculators available to predict the risk of 
bleeding that could have been used in the trials to identify patients at risk of bleeding. 
These include the HASBLED score, extensively validated with OAC, albeit 
predominantly in patients with AF and scores assessing bleeding with antiplatelet 
agents such as DAPT score (Dual Antiplatelet Therapy)(58) and the PARIS score 
(Patterns of Non-Adherence to Anti-Platelet Regimen in Stented Patients)(59) which 
use a variety of clinical and angiographic factors in order to predict the risk of 
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ischaemic events and bleeding. The PRECISE-DAPT (Derivation and validation of 
the predicting bleeding complications in patients undergoing stent implantation and 
subsequent dual antiplatelet therapy)(60) is a relatively new five clinical point score 
that can be used to predict bleeding events in patients receiving DAPT. Overall, 
CRUSADE(61) and ACUITY(62) scores have reasonable predictive value for major 
bleeding in ACS patients undergoing coronary angiography, with the CRUSADE 
score considered the most discriminatory. However, in patients medically treated or 
on oral anticoagulants, the predictive value of these scores is not established. 
 
Definition of bleeding 
 
Also pertinent is that different studies reported here have used different definitions of 
bleeding, with a lack of uniformity among the trials, making relative comparisons of 
bleeding risk with different agents impossible. Bleeding events, classified as in the 
studied by the GUSTO(63), ISTH(64), TIMI(65) or CURE(8) bleeding risk scores 
have included laboratory parameters, such as decrease in haemoglobin, and clinical 
events, including the need for transfusion or surgery, cardiac tamponade, 
haematomas, and various degrees of bleeding. Each definition incorporates a different 
combination of these elements and then ranks orders these combinations into severity 
categories, which vary widely between definitions. To standardise the reporting of 
bleeding events between studies, the Bleeding Academic Research Consortium was 
convened and published guidelines that should now be used, but were not available at 
the time of some of these publications(66). 
 
 
	 19	
Dosing 
 
A further consideration is that the dose of apixaban in all the ACS studies was based 
on the previously effective full anticoagulation dose used for atrial fibrillation in the 
ARISTOTLE trial(67). On the other hand, the rivaroxaban dose employed in the 
ATLAS studies was only one-quarter to one-half the anticoagulant treatment dose 
used in the ROCKET-AF trial(68). Although a reduced bleeding rate would be 
expected with a lower dose of anticoagulation, in both the ATLAS ACS-TIMI 51 and 
APPRAISE-2 trials the increase in the rate of bleeding was still significant(46, 48). 
Moreover, the observed benefit in MACE reduction was noted with the lower 
effective dose in ATLAS ACS-TIMI 51 and not with the higher dose in both ATLAS 
ACS-TIMI 51 and APPRAISE-2, a finding that is not easy to understand(46, 48). 
 
Heterogeneous patient group 
 
The studies have been focused on ACS patients, but no real attempt has been made to 
focus on those patients with ACS who are at highest risk of recurrent events.  
Patients included in all studies had a recent ACS and one or more additional risk 
factor, apart from ATLAS ACS-TIMI 46 and ATLAS ACS-TIMI 51(45, 46). In 
ATLAS ACS-TIMI 46 patients were included with no risk factors for future MACE 
and in the ATLAS ACS-TIMI 51 subjects were required to have a history of either 
diabetes mellitus or a prior MI.  
Another interesting observation is that patients in the APPRAISE-2(48) trial were at 
higher risk of recurrent events, with a higher proportion of female patients (32.2%), 
and almost half the population were diabetic. However, less than half the population 
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underwent PCI for their index event, which appears relatively low and suggests, 
perhaps, that insufficient revascularisation may have contributed to recurrent events, 
that may have masked the potential benefit of triple therapy(6, 32, 69). 
 
Identifying and targeting high risk patients 
 
Several risk stratification scores have been suggested to assess the risk of recurrent 
ischaemic events in patients with ACS.  These include the GRACE score (Global 
Registry of Acute Cardiac Events), the PURSUIT score (Platelet glycoprotein IIb/IIIa 
in Unstable angina: Receptor Suppression Using Integrilin Therapy) the TIMI score 
(Thrombolysis in Myocardial Infarction) consisting of a variation of clinical and 
angiographic risk factors.  
 
 
Choice of P2Y12 inhibitor 
 
The choice of P2Y12 inhibitor in the DAPT and triple therapy arms of the study may 
be relevant. Most ACS studies included patients that received a combination of 
aspirin and clopidogrel(45-52). Contemporary evidence-based medicine recommends 
more potent P2Y12 inhibitors ticagrelor or prasugrel in ACS, rather than clopidogrel, 
due to their superiority in reducing the risk of further MACE(32) (11) (13). It 
therefore suggests that the combination of triple therapy with DAPT and a NOAC 
should be compared to a control arm that comprised DAPT with ticagrelor or 
prasugrel, and not clopidogrel. A very recent systematic review and network meta-
analysis of 47 randomised controlled trials of nearly 200,000 participants with ACS 
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showed that compared to aspirin monotherapy, only the combination of aspirin with 
ticagrelor was reduced cardiovascular mortality (OR 0.80, 95% CI 0.68–0.93), whilst 
the combination of aspirin, clopidogrel, and very low dose rivaroxaban reduced all-
cause mortality (OR 0.67, 95% CI 0.49–0.90)(56).There is intuitive fear that the 
combination of a NOAC with DAPT that includes these more potent P2Y12 inhibitors 
will likely increase bleeding compared to clopidogrel, but this is by no means 
guaranteed. Although prasugrel reduced MACE compared to clopidogrel in ACS 
patients in the TRITON-TIMI 38 at a cost of increased bleeding(11) , ticagrelor 
reduced MACE compared to clopidogrel without significant increase in bleeding(13). 
Comparisons of triple therapy including ticagrelor versus clopidogrel have not shown 
a difference in bleeding(70) and the results of the GEMINI-ACS-1 study are also 
encouraging (vide infra). 
 
Clinical efficacy endpoints 
 
There has also been heterogeneity in the primary efficacy outcomes (Table 1) with 
some studies including only ischaemic strokes and others all strokes, some including 
all-cause mortality and others only CV death, and some others including the need for 
revascularisation.  
 
 
Conclusions 
 
 
In patients with a recent ACS where DAPT is the current standard of care, the use 
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instead of triple therapy, with addition of an oral anticoagulant, PAR1 antagonist or 
cilostazol, has been investigated with the aim of reducing future ischaemic events. 
Triple therapy leads to a significant increase in bleeding, and this is unacceptably high 
with vorapaxar and with warfarin. Low dose rivaroxaban 2.5 mg twice daily can be 
considered in combination with aspirin and clopidogrel for ACS patients who have 
high ischaemic and low bleeding risk. There is a clear signal that triple therapy can, at 
times, reduce ischaemic events, but the excessive bleeding seems to exceed the 
potential benefit. There is an absolute necessity for accurate risk stratification of these 
patients, both in terms of risk of future ischaemic events as well as bleeding, to allow 
targeted, individualised treatment.  
 
 
Future directions 
 
Future trials should focus on identifying patients at high risk of recurrent adverse 
ischaemic events, who may gain most from more potent antithrombotic agent 
combinations. 
In addition to GRACE and TIMI risk scores in ACS patients, several angiographic 
markers of recurrent thrombosis, such as stent diameter and length of stented segment 
or stent under-expansion, as well as completeness of revascularisation, could be 
incorporated into risk assessment. 
Platelet function tests may have a role in identifying patients at high risk of future 
ischaemic events. Multiple large observational studies have described the association 
between HTPR while on clopidogrel and increased rates of nonfatal MI, 
definite/probable stent thrombosis, and CV mortality(71, 72). In the ADAPT-DES 
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(Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents) study of 8,582 
patients undergoing PCI with DAPT, 51.7% presented with ACS. HTPR was an 
independent predictor of stent thrombosis (HR 2.49, p = 0.001) and MI (HR 1.42, 
95% CI 1.09-1.86; p=0.01) at 1 year, but not a predictor of mortality(73). Although 
there is very limited data to support the concept that alterations of therapy based on 
platelet function measurements improve clinical outcome, this should not deter from 
using platelet function tests to identify patients at high risk of ischaemic events that 
may benefit from more aggressive pharmacotherapy. 
Since bleeding remains a concern with more potent combinations of agents, accurate 
bleeding risk stratification and perhaps mandated prophylactic use of proton-pump 
inhibitors should be seriously considered. 
Another newer antiXa inhibitor, edoxaban is currently been evaluated in a phase II 
trial, together with aspirin and clopidogrel, in patients with ACS(74). 
The recently published GEMINI-ACS study was a phase II randomised controlled 
trial, of 3037 patients with ACS assessing the effect of the newer P2Y12 inhibitors in 
addition to aspirin or NOAC(75). Patients were randomised to receive aspirin or low 
dose 2.5mg b.i.d rivaroxaban in addition to clopidogrel or ticagrelor. There was no 
significant difference between rivaroxaban and aspirin with respect to the primary 
endpoint of clinically significant (non-CABG related) bleeding (HR 1.09; p=0.548). 
Moreover, amongst patients receiving ticagrelor, there was no significant difference 
in bleeding whether combined with aspirin or rivaroxaban, and no difference when 
compared to the clopidogrel arm. Of note, the bleeding rates were non-significantly 
higher for the ticagrelor group, and would need to be addressed in a larger study in 
order to assess the safety of the combination treatment with rivaroxaban and 
ticagrelor. Nevertheless, the combination of P2Y12 inhibitor and NOAC seems 
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promising. The concept of DAPT may be replaced, not by triple therapy, but by dual 
therapy comprising an OAC with a P2Y12 inhibitor.  
The challenge is not only to find the right combination, but also to get it to the right 
patient. 
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Figure 1: Platelet activation and aggregation in response to endothelial injury following plaque 
rupture in acute coronary syndrome 
GP: glycoprotein, TxA2: thromboxane, TF: tissue factor, PAR: protease activated receptor  
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Figure 2: Activated coagulation pathway and common sites of anticoagulant action 
TF: transfer factor, GP: glycoprotein 
